01—Abstract
Summary
Summary of the 10-K filed February 28, 2007. Cited figures are marked; the original filing is the authoritative source.
Incyte Corporation's 10-K for fiscal 2006 describes a drug discovery and development company focused on small molecule drugs for serious unmet medical needs, with programs in HIV, diabetes, oncology and inflammation.
The company reported 2006 total revenues of $27.6 milliona, consisting of $24.2 million of contract revenues from its January 2006 collaboration with Pfizer and $3.4 million of license and royalty revenues, against total costs and expenses of $104.5 million. Research and development expense was $87.6 million, and the net loss narrowed to $74.2 million, or $0.89 per share, from $103.0 million in 2005. The company expects to keep incurring losses and states that none of its drug candidates has been submitted for regulatory approval, and it had no drug products generating revenue to date.
The balance sheet shows cash, cash equivalents and marketable securities of $329.8 millionb at December 31, 2006, against an accumulated deficit of $913.5 million and a stockholders' deficit of $84.9 million. Total debt principal was $411.8 million, including $151.8 million of 3½% convertible senior notes due 2011 issued in September 2006, $250.0 million of 3½% convertible subordinated notes due 2011, and a $10.0 million non-interest-bearing Pfizer note due 2013. Management states that cash and marketable securities should be adequate for at least the next twelve months, and net cash used in operating activities improved to $50.4 million in 2006 from $101.9 million in 2005, largely due to the $40.0 million Pfizer upfront payment.
Pfizer holds worldwide development and commercialization rights to the CCR2 antagonist portfolio, excluding multiple sclerosis and lupus nephritis, and Incyte is eligible for up to $743.0 millionc in future development and milestone payments. The company discontinued its DFC HIV program in April 2006, and its most advanced candidates are in Phase I and Phase IIa trials.
02—Key points
Key Highlights
- Net loss narrowed to $74.2 million ($0.89 per share) in 2006 from $103.0 million ($1.24 per share) in 2005.
- Total revenues were $27.6 million in 2006, including $24.2 million of Pfizer-related contract revenues, versus $7.8 million in 2005.
- Cash, cash equivalents and marketable securities totaled $329.8 million at December 31, 2006.
- Total debt principal was $411.8 million, and the stockholders' deficit was $84.9 million at year-end 2006.
- Pfizer collaboration on CCR2 antagonists includes a $40.0 million upfront payment and up to $743.0 million in potential future development and milestone payments.
- Net cash used in operating activities fell to $50.4 million in 2006 from $101.9 million in 2005.
- The company discontinued development of DFC in April 2006, and no drug candidate has yet been submitted for regulatory approval.
03—Questions
Frequently Asked Questions
Is Incyte generating product revenue from its drugs?
No. The filing states that none of its drug candidates has been submitted for approval in the United States or any foreign market, and that it does not expect product sales from its drug discovery and development efforts for several years, if at all. 2006 revenues came from the Pfizer collaboration and from license and royalty income tied to its legacy information products.
How much cash does Incyte have and is it enough?
The company reported $329.8 million in cash, cash equivalents and marketable securities at December 31, 2006. Management believes this is adequate to satisfy its capital needs for at least the next twelve months, though it notes that future cash needs depend on factors including debt repayments, drug development spending and litigation.
What are Incyte's main debt obligations?
As of December 31, 2006, the company had $151.8 million principal of 3½% convertible senior notes due 2011, $250.0 million of 3½% convertible subordinated notes due 2011, and a $10.0 million Pfizer convertible subordinated note due 2013. Annual interest on the senior notes through 2010 is $5.3 million and on the subordinated notes is $8.8 million, assuming no conversion, redemption or repurchase.
What is the status of the Pfizer collaboration?
Under the January 2006 agreement, Pfizer gained worldwide development and commercialization rights to Incyte's CCR2 antagonist portfolio, except for multiple sclerosis and lupus nephritis, for which Incyte retained rights. Incyte received a $40.0 million upfront payment and is eligible for up to $743.0 million in future development and milestone payments plus royalties. The filing notes Pfizer may terminate the license on 90 days' notice.
What are the key risks highlighted in the filing?
The filing emphasizes the early stage of its pipeline, with most candidates in Phase I or Phase IIa trials, the risk of clinical failure and regulatory delays, dependence on Pfizer for CCR2 development, need for additional capital, a large debt load, and continued operating losses. It also cites intense competition from larger pharmaceutical companies and the risk of patent challenges.
04—Continue